Agios Pharmaceuticals Inc (AGIO)
22.66
-0.60 (-2.58%)
USD |
NASDAQ |
Mar 20, 14:07
Agios Pharmaceuticals Total Assets (Quarterly): 1.239B for Dec. 31, 2022
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2022 | 1.239B |
| September 30, 2022 | 1.180B |
| June 30, 2022 | 1.252B |
| March 31, 2022 | 1.336B |
| December 31, 2021 | 1.438B |
| September 30, 2021 | 1.541B |
| June 30, 2021 | 1.875B |
| March 31, 2021 | 2.488B |
| December 31, 2020 | 852.95M |
| September 30, 2020 | 908.45M |
| June 30, 2020 | 976.14M |
| March 31, 2020 | 799.74M |
| December 31, 2019 | 890.74M |
| September 30, 2019 | 698.62M |
| June 30, 2019 | 783.87M |
| March 31, 2019 | 822.13M |
| December 31, 2018 | 858.46M |
| September 30, 2018 | 929.08M |
| June 30, 2018 | 998.24M |
| March 31, 2018 | 1.040B |
| December 31, 2017 | 614.40M |
| Date | Value |
|---|---|
| September 30, 2017 | 687.20M |
| June 30, 2017 | 760.60M |
| March 31, 2017 | 557.32M |
| December 31, 2016 | 619.09M |
| September 30, 2016 | 672.04M |
| June 30, 2016 | 557.60M |
| March 31, 2016 | 396.12M |
| December 31, 2015 | 420.06M |
| September 30, 2015 | 449.09M |
| June 30, 2015 | 474.38M |
| March 31, 2015 | 474.34M |
| December 31, 2014 | 491.90M |
| September 30, 2014 | 269.61M |
| June 30, 2014 | 272.03M |
| March 31, 2014 | 181.91M |
| December 31, 2013 | 201.20M |
| September 30, 2013 | 219.07M |
| June 30, 2013 | 111.25M |
| March 31, 2013 | 125.85M |
| December 31, 2012 | 137.01M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
698.62M
Minimum
Sep 2019
2.488B
Maximum
Mar 2021
1.145B
Average
987.19M
Median
Total Assets (Quarterly) Benchmarks
| Moderna Inc | 25.86B |
| Alnylam Pharmaceuticals Inc | 3.546B |
| Cassava Sciences Inc | 234.83M |
| Regeneron Pharmaceuticals Inc | 29.21B |
| Karyopharm Therapeutics Inc | 358.17M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 137.90M |
| Shareholders Equity (Quarterly) | 1.101B |
| Current Ratio | 13.30 |